Captopril-furosemide survival study in experimental heart failure

Area of Science:

• Cardiology
• Pharmacology
• Renal Medicine

Background:

• The role of diuretic therapy alongside neurohormonal blockade in heart failure management requires further definition.
• The impact of combined diuretic and angiotensin-converting enzyme (ACE) inhibition on survival in heart failure is not well-established.

Purpose of the Study:

• To investigate the cardiovascular and renal effects of adding diuretic treatment to captopril in an experimental heart failure model.
• To evaluate the impact of this combination therapy on animal survival.

Main Methods:

• Utilized a rat model of heart failure induced by coronary ligation, followed for 10 months.
• Assessed survival rates, echocardiographic and hemodynamic parameters, morphometry, and renal function in surviving rats.
• Administered captopril in drinking water, with or without furosemide.

Main Results:

• Survival rates increased from 34% to 61% in the captopril + furosemide group compared to controls.
• Combination therapy significantly improved cardiac dimensions and left ventricular fractional shortening.
• Diuresis, natriuresis, and heart rate were enhanced, while blood pressure was reduced; kidney weight increased.

Conclusions:

• The combination of captopril and furosemide significantly improved cardiac remodeling and survival in this heart failure model.
• This drug combination enhanced diuresis and natriuresis despite increased plasma renin activity and kidney hypertrophy.
• The findings suggest a beneficial role for combined diuretic and ACE inhibitor therapy in heart failure management.